Figure S1 - Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients

Factor VIII-deficient mice were treated with vehicle or recombinant IL-11 for 7 consecutive days. VWF levels remained unchanged in vehicle-treated mice, but were increased 1.7-fold in IL-11 treated mice. Mice were subsequently injected intravenously with recombinant VWF-free FVIII (150 U/kg), and blood samples were taken at indicated time-points. The graph displays residual FVIII levels at indicated time-points for both vehicle- and IL-11 treated mice. At none of the indicated time-points, a statistical significant difference in residual FVIII activity was detected. Data represent mean��SD of 3 mice per time-point. (0.03 MB PDF)